HKG: 2137

Company Drug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

Fineline Cube Jul 27, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...

Company Deals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

Fineline Cube Jul 19, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...

Company Drug

Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China

Fineline Cube Jul 7, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19...

Company Deals Drug

Brii Biosciences Exercises Option for VIR-3434 in Greater China

Fineline Cube Jul 4, 2022

China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance